Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of selective fragment-sized immunoproteasome inhibitors
Levente Kollár, Martina Gobec, Bence Szilágyi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 219, pp. 113455-113455
Closed Access | Times Cited: 13

Showing 13 citing articles:

Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Laura Hillebrand, Xiaojun Julia Liang, Ricardo A. M. Serafim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7668-7758
Closed Access | Times Cited: 49
Recent Advances in the Development of Immunoproteasome Inhibitors as Anti-Cancer Agents: The Past 5 Years
Francesca Mancuso, Carla Di Chio, Francesca Di Matteo, et al.
Molecules (2025) Vol. 30, Iss. 3, pp. 755-755
Open Access | Times Cited: 2
Thioamides in medicinal chemistry and as small molecule therapeutic agents
G. Huang, Tomasz Cierpicki, Jolanta Grembecka
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116732-116732
Closed Access | Times Cited: 6
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds
Matic Proj, Damijan Knez, Izidor Sosič, et al.
Drug Discovery Today (2022) Vol. 27, Iss. 6, pp. 1733-1742
Open Access | Times Cited: 19
Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Anti‐SARS‐CoV‐2 Activity
Bianca Schulte, Maria König, Beate I. Escher, et al.
ChemMedChem (2022) Vol. 17, Iss. 5
Open Access | Times Cited: 14
Targeting immunoproteasome in neurodegeneration: A glance to the future
Grazia R. Tundo, Paolo Cascio, Danilo Milardi, et al.
Pharmacology & Therapeutics (2022) Vol. 241, pp. 108329-108329
Closed Access | Times Cited: 8
Masking thiol reactivity with thioamide, thiourea, and thiocarbamate-based MBPs
Hyeonglim Seo, Alysia J. Kohlbrand, Ryjul W. Stokes, et al.
Chemical Communications (2023) Vol. 59, Iss. 16, pp. 2283-2286
Open Access | Times Cited: 4
Selective noncovalent proteasome inhibiting activity of trifluoromethyl‐containinggem‐quaternary aziridines
Laura Ielo, Vincenzo Patamia, Andrea Citarella, et al.
Archiv der Pharmazie (2023) Vol. 356, Iss. 7
Open Access | Times Cited: 3
Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment
Yu Cao, Yutong Tu, Liping Fu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 233, pp. 114211-114211
Closed Access | Times Cited: 5
Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
Levente Kollár, Martina Gobec, Matic Proj, et al.
Cells (2021) Vol. 10, Iss. 12, pp. 3431-3431
Open Access | Times Cited: 7
Structure-based mapping of the histone-binding pocket of KDM4D using functionalized tetrazole and pyridine core compounds
P.H. Malecki, Georg M. Fassauer, Nicole Rüger, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116642-116642
Open Access
Design and synthesis of amino-substituted N-arylpiperidinyl-based inhibitors of the (immuno)proteasome
Martina Gobec, Aleš Obreza, Marko Jukič, et al.
Acta Pharmaceutica (2023) Vol. 73, Iss. 3, pp. 441-456
Open Access | Times Cited: 1
Molecular Mechanism of Labelling Functional Cysteines by Heterocyclic Thiones
Levente M. Mihalovits, Levente Kollár, Dávid Bajusz, et al.
ChemPhysChem (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Page 1

Scroll to top